Resources

Trachoma is the leading cause of infectious blindness in the world. The infectious agent of trachoma is the bacteria Chlamydia trachomatis that spreads by contact with an infected person’s hands or clothing. Infection leads to conjunctival inflammation that produces trachoma follicles visible on physical exam. Yet it is the repeated episodes of reinfection and inflammation that lead to scarring, distortion of the eyelid, and in-turning of the lid with the eyelashes touching the cornea, called trichiasis, that leads to blindness. Infectious spread is prevented by good hygiene practices, including hand and face cleanliness, and environmental improvements. Antibiotics, namely oral azithromycin or topical tetracycline, are an effective treatment of active trachoma infections, while surgery is indicated to manage trichiasis.The Alliance for Global Elimination of Blinding Trachoma by 2020 (GET 2020), led by the World Health Organization (WHO), developed the SAFE strategy to reach their goal of eliminating trachoma by 2020 through Surgery, Antibiotics, Facial cleanliness, and Environmental improvement.2 The most commonly used antibiotic for trachoma, oral azithromycin, is donated free of charge by the pharmaceutical company Pfizer and is given to entire communities. In order to assess the impact of the community-wide antibiotic distribution, commonly known as mass drug administration (MDA), trachoma surveillance is performed with a physical exam of the eye. This method of diagnosis is acceptable for early control programs; however, as we move closer to elimination of trachoma, more sensitive and specific diagnostics are needed.This report proposes a target product profile (TPP) for the development of a new diagnostic technology that facilitates accurate post-elimination surveillance. Each attribute has an “acceptable” standard that must be met and an “ideal” standard that, if met, would maximize the target product’s value. This TPP focuses on the development of a lateral flow rapid diagnostic test (RDT) that detects trachoma antibodies.As reference, for a description of the currently available nucleic acid amplification tests for trachoma, please see Appendices A-1 and A-2

This fact sheet provides an overview of rotavirus disease and vaccines in Tajikistan. It includes information about the tremendous burden of rotavirus diarrhea in Tajikistani children, rotavirus diarrhea treatment and prevention strategies, and the effectiveness of rotavirus vaccines.

Vaccine and Pharmaceutical Technologies News and Updates provides semiannual briefings on PATH’s work to advance innovative technologies that help to improve vaccine and pharmaceutical products and the way they are delivered, especially in remote settings with limited access to health facilities and refrigeration equipment.

A Healthy Dose from PATH’s Drug Development program gives advocates, policymakers, government and agency leaders, and anyone interested in global health a quarterly update on our work. Each issue features reports from the field, news on the latest clinical trial milestones, and resources in nonprofit drug development.

DefeatDD.org’s 3D News: Perspectives on Defeating Diarrheal Disease provides news and views for advocates, program implementers, policymakers, and anyone interested in the growing momentum for defeating the second-leading killer of children worldwide. The newsletter offers the latest on interventions and solutions, profiles of partners and success stories, summaries of recently published reports, upcoming events, and more.